• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe

Abbott

Abbott gets FDA nod for longer length Esprit BTK drug-eluting scaffold

July 13, 2026 By Sean Whooley

Abbott (NYSE:ABT) announced today that the FDA approved the longer length (76 mm) Esprit BTK drug-eluting scaffold system. The longer Esprit BTK system received approval for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD). CLTI can cause extreme pain, open wounds that don’t heal and, in some cases, […]

Filed Under: Cardiac Implants, Cardiovascular, Drug-Device Combinations, Drug-Eluting Stents, Food & Drug Administration (FDA), Implants, Regulatory/Compliance, Stents, Structural Heart, Vascular Tagged With: Abbott, FDA

AtaCor treats first patient in EV-ICD lead study in partnership with Abbott

July 7, 2026 By Sean Whooley

AtaCor Medical announced today that it enrolled the first patient in its ALARION-EV extravascular implantable cardioverter-defibrillator (EV-ICD) trial. ALARION-EV evaluates a next-generation parasternal EV-ICD system. It features AtaCor’s Atala lead in combination with an EV-ICD pulse generator developed by Abbott. The study evaluates the system in patients indicated for a standard ICD but do not […]

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Implants, Structural Heart, Structural Heart Tagged With: Abbott, AtaCor Medical

Tandem Diabetes Care launches t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in new geographies

July 1, 2026 By Sean Whooley

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it launched the t:slim X2 insulin pump with the Abbott FreeStyle Libre 3 Plus in five new countries. San Diego-based Tandem launched the pairing of its flagship automated insulin delivery system with Control-IQ+ technology with Abbott’s latest continuous glucose monitor (CGM) sensor in the U.S. in October 2025. […]

Filed Under: Diabetes, Drug Pumps, Drug-Device Combinations, Health Technology, Patient Monitoring Tagged With: Abbott, Tandem Diabetes Care

Abbott data backs TriClip, Navitor, next-gen Amulet systems

June 26, 2026 By Sean Whooley

Abbott (NYSE:ABT) today shared new findings supporting its TriClip, Navitor and investigational Amulet 360 systems. The medtech giant shared its findings at New York Valves 2026: The Structural Heart Summit, in multiple presentations. Abbott’s TriClip transcatheter edge-to-edge repair (TEER) offers an option for those who aren’t good candidates for surgery and continue to have symptoms or […]

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Featured, Implants, Replacement Heart Valves, Structural Heart, Structural Heart Tagged With: Abbott

CMS proposes TAVR coverage update that benefits Edwards, Medtronic, Abbott

June 16, 2026 By Sean Whooley

The U.S. Centers for Medicare and Medicaid Services (CMS) has proposed an update to its coverage for transcatheter aortic valve replacement (TAVR) therapy. CMS proposed an update to its National Coverage Determination (NCD), having initiated a review in December 2025 after accepting a request from TAVR leader Edwards Lifesciences for an NCD update. The proposal, […]

Filed Under: Business/Financial News, Cardiac Implants, Cardiovascular, Featured, Implants, Replacement Heart Valves, Structural Heart, Structural Heart Tagged With: Abbott, Centers for Medicare and Medicaid Services (CMS), CMS, Edwards Lifesciences, Medtronic, nitinol

The biggest diabetes tech news out of ADA 2026

June 10, 2026 By Sean Whooley

The biggest names in diabetes tech gathered in New Orleans last weekend for the American Diabetes Association’s 86th Scientific Sessions (ADA 2026). Clinical findings supporting next-generation automated insulin delivery platforms, continuous glucose monitors (CGMs) and all kinds of other technologies were on display in New Orleans. BTIG analysts Marie Thibault, Alexandra Pang and Sam Eiber […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug Pumps, Drug-Device Combinations, Featured, Health Technology, Patient Monitoring, Software / IT Tagged With: Abbott, ADA 2026, Adaptyx, Beta Bionics, biolinq, Dexcom, Insulet, Mannkind Corp., MiniMed, Senseonics, Tandem Diabetes Care, Terrestrial Bio, Tidepool

Abbott launches next-gen CardioMEMS Hero pulmonary artery pressure reader in US

June 8, 2026 By Sean Whooley

Abbott (NYSE:ABT) said today that it launched its CardioMEMS HERO Device, a next-generation pulmonary artery (PA) pressure reader in the U.S. In a LinkedIn post, the medtech giant wrote: “Our CardioMEMS HERO Device is now available in the U.S. With simple setup and easy connection, this smaller and lighter patient reader is designed to support […]

Filed Under: Cardiac Implants, Cardiovascular, Diagnostics, Health Technology, Implants, Patient Monitoring, Structural Heart Tagged With: Abbott

Insulet launches enhanced Omnipod 5 algorithm, expands Abbott compatibility

June 3, 2026 By Sean Whooley

Insulet (Nasdaq:PODD) announced today that it is rolling out new algorithm enhancements for its Omnipod 5 automated insulin delivery system. The company also expanded its compatibility with Abbott sensors, adding the option of pairing Omnipod 5 with FreeStyle Libre 3 Plus. Acton, Massachusetts-based Insulet won FDA clearance for its algorithm enhancements in December 2025. The […]

Filed Under: Business/Financial News, Diabetes, Drug Pumps, Drug-Device Combinations, Health Technology, Patient Monitoring, Software / IT Tagged With: Abbott, Insulet

MiniMed adds Abbott dual glucose-ketone sensor to portfolio, posts Q4 sales beat

June 3, 2026 By Sean Whooley

MiniMed (Nasdaq:MMED) announced today that it expanded its agreement with Abbott (NYSE:ABT) to add more sensors to its portfolio. The company also announced fourth-quarter earnings results in tandem with the new Abbott integration. MiniMed has an existing partnership with Abbott through a collaboration between the companies agreed in 2024. They integrated Instinct, a sensor made by […]

Filed Under: Business/Financial News, Diabetes, Drug Pumps, Drug-Device Combinations, Featured, Health Technology, MassDevice Earnings Roundup, Patient Monitoring, Wall Street Beat Tagged With: Abbott, MiniMed

Abbott wins CE mark for dual glucose-ketone sensor

May 27, 2026 By Sean Whooley

Abbott (NYSE:ABT) announced today that it received CE mark approval for its dual glucose-ketone sensing technology for people with diabetes. The company said its dual sensor marks a world first, continuously measuring glucose and ketone levels every minute. Branded as Libre Duo and Libre Duo 10 Day, the sensors provide real-time visibility into glucose levels […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Health Technology, Patient Monitoring, Regulatory/Compliance Tagged With: Abbott

The top stories from EuroPCR 2026

May 26, 2026 By Sean Whooley

EuroPCR 2026 brought together a range of treatment developers across interventional cardiology in Paris last week. Technologies on display included intravascular lithotripsy (IVL) systems, transcatheter heart valves, renal denervation (RDN) technologies, drug-eluting stents and more. Usual big names in the cardiovascular space like Medtronic, Boston Scientific and Abbott shared updates. Meanwhile, innovators like Jupiter Neurovascular, […]

Filed Under: Cardiac Implants, Cardiovascular, Catheters, Clinical Trials, Drug-Eluting Stents, Featured, Health Technology, Imaging, Replacement Heart Valves, Software / IT, Stents, Structural Heart Tagged With: Abbott, Boston Scientific, Elixir Medical, Jupiter Endovascular, Medtronic, Philips, ReFlow Medical

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 123
  • Go to Next Page »

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

Image

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy